Peter Ansell

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Robert L. Coleman, Gini F. Fleming, Mark F. Brady et al. · New England Journal of Medicine · 2019 · 929 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Activation of p53 by MEG3 Non-coding RNA

Yunli Zhou, Ying Zhong, Yingying Wang et al. · Journal of Biological Chemistry · 2007 · 650 citations · Full text

Medicine, Molecular Biology, Oncology +16

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

Dalia L. Batista, Xun Zhang, Roger Gejman et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 200 citations

Medicine, Endocrinology, Pathology +17

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang et al. · Neuro-Oncology · 2022 · 147 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Martin J. van den Bent, Hui Gan, Andrew B. Lassman et al. · Cancer Chemotherapy and Pharmacology · 2017 · 135 citations · Full text

Medicine, Oncology, Pharmacology +17